MiCareo Inc.

Company Snapshot

Founded: 2011
Entity Type: Private
Region: Taiwan
Headquarter: Taipei City, Taiwan (R.O.C.)
Key Geographics: North America, Asia
Corporate Address: 5F, No. 69, Lane 77 Xing Ai Road, Neihu District Taipei City 114, Taiwan (R.O.C.) Tel. +886-2-2792-3976 www.micareo.com

Company Overview

MiCareo Inc. is developing and marketing liquid biopsy tools and technologies for isolating live rare cells and automating multiplexed fluorescence imaging.

The MiSelect R System can be used by researchers to give them access to rare cells, CTCs and immune cells for liquid biopsy research and single-cell downstream analysis. The platform provides a way to capture and analyze isolated live rare cells to allow for noninvasive real-time monitoring.

MiCareo Inc. In Reports

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

Discover BCC Research's report on Next-generation Sequencing Market is steadily being integrated into clinical laboratory analysis, testing, and disease diagnostics in healthcare sectors globally.

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

BCC Research Market Report says clinical next-generation sequencing (NGS) should grow from $5.9 billion in 2020 to $22.9 billion by 2025 with a (CAGR) of 31.4%.

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

BCC Market Research Report for global liquid biopsy research tools, liquid biopsy biomarkers, technologies, services and diagnostics markets.

Company's Business Segments

  • Biopsy Tools and Solutions : The company provides advanced tools for liquid biopsy, focusing on the isolation and analysis of rare cells such as circulating tumor cells (CTCs) for cancer prognosis, treatment development, and efficacy evaluation.

Applications/End User Industries

  • Healthcare
  • Oncology
  • Biopsy
  • Diagnosis
  • Medical Testing
  • Life Sciences
AI Sentiment